Loading stock data…
CNTA
$39.59-0.02 (-0.05%)
Market ClosedLast close May 8
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Centessa Pharmaceuticals plc in the Healthcare sector is trading at $39.59. The stock is currently near its 52-week high of $40.26, remaining 53.7% above its 200-day moving average. Technical signals show neutral RSI of 56 and bearish MACD signal, explaining why CNTA maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$39.59
Potential Upside
5%
Whystock Fair Value$41.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$44.57+12.6%
Range$38.00 – $62.00
Fundamentals
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.73%
Volume
Today's trading volume
681,276
Recent News
Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for the next 15 years. On May 7, Eli Lilly executed its largest bond issuance to date, selling $9 billion in investment-grade debt to fund a recent surge in acquisitions. The offering, which initially targeted $8 billion, saw high investor demand following […]
Eli Lilly Sells $9 Billion of Bonds to Fund Acquisitions
(Bloomberg) -- Eli Lilly & Co. sold $9 billion of investment-grade bonds Wednesday — the company’s biggest-ever issuance — as it looks to finance an acquisition spree. Most Read from BloombergUS Has Opened a Passage Through Hormuz, Central Command SaysDOJ Plans Intervention in Trump Supreme Court Carroll AppealUS Says Offensive Phase of Iran War Over as Ship Hit in StraitAnthropic Unveils AI Agents to Field Financial Services TasksStocks Hit All-Time Highs on Hopes War Is Near End: Markets WrapT
Update: Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions
(Updates with the company's response in the fourth paragraph.) Eli Lilly (LLY) is looking to rais
Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge?
For investors wondering if Centessa Pharmaceuticals at around US$39.57 still offers value, or if most of the opportunity is already priced in, this article breaks down what the current share price might be implying. The stock has seen a 0.3% return over the last week, a small 0.3% decline over the last month, and a 67.0% return year to date and 190.7% over the past year. This puts a lot of attention on whether those gains are supported by fundamentals or sentiment. Recent coverage has...
Guggenheim Raises PT on Eli Lilly (LLY) Amid Several Acquisition Deals
Backed by one-year EPS and revenue growth estimates of 21.72% and 16.23%, respectively, Eli Lilly and Company (NYSE:LLY) ranks among the best growth stocks to buy and hold in 2026. As of April 23, 2026, a majority of analysts covering the stock have a Buy rating on it; that is, 77% of all covering analysts, […]